Table 4.

Unadjusted and confounder-adjusted analysis of the association between interpregnancy interval and blood-based cardiovascular risk factors using multivariate multiply imputed data (N=1268)

		Interpregnancy interval
	Analysis model number	≤15 months		16–27 months	>27 months
		β* (95% CI)	p Value	Ref group	β* (95% CI)	p Value
Cholesterol (mmol/L)	Model 1†	−0.1 (−0.2 to 0.1)	0.3	0	−0.1 (−0.2 to 0.03)	0.1
	Model 2‡	−0.1 (−0.3 to 0.1)	0.2	0	−0.05 (−0.2 to 0.1)	0.4
HDL (mmol/L)	Model 1†	0.03 (−0.04 to 0.1)	0.4	0	−0.01 (−0.1 to 0.05)	0.8
	Model 2‡	0.03 (−0.04 to 0.1)	0.4	0	0.01 (0 to 0.1)	0.6
		Per cent change (95% CI)	p Value	Ref group	Per cent change (95% CI)	p Value
Insulin (µ/L)§	Model 1†	1 (0.9 to 1.1)	0.8	0	1.1 (1 to 1.2)	0.1
	Model 2‡	1 (0.9 to 1.1)	0.9	0	1 (1 to 1.1)	0.4
Proinsulin (pmol/L)§	Model 1†	1 (0.9 to 1.1)	0.7	0	1.1 (1 to 1.1)	0.1
	Model 2‡	1 (0.9 to 1.1)	0.8	0	1 (1 to 1.1)	0.2
Triglyceride (mmol/L)§	Model 1†	0.9 (0.9 to 1)	0.1	0	0.9 (0.9 to 1)	0.03
	Model 2‡	0.9 (0.9 to 1)	0.1	0	0.9 (0.9 to 1)	0.02
CRP (mg/L)§	Model 1†	0.9 (0.8 to 1.1)	0.4	0	1.1 (0.9 to 1.2)	0.4
	Model 2‡	0.9 (0.8 to 1.1)	0.5	0	1 (0.9 to 1.2)	0.6
Glucose (mmol/L) §	Model 1†	1 (1 to 1)	0.7	0	1 (1 to 1)	0.4
	Model 2‡	1 (1 to 1)	0.6	0	1 (1 to 1)	0.3

*Mean difference compared with 16–27 months.

†Unadjusted model.

‡Adjusted for maternal age, maternal ethnicity, social class, education, pre-pregnancy BMI, ever smoking during pregnancy.

§Log transformed.

BMI, body mass index; CRP, C reactive protein; HDL, high-density lipoprotein.